New medicine for Orphan and Rare Diseases has the capability to undoubtedly impact the lives of patients, where historically there were few or no treatments have been provided to control the sickness. The Orphan Drug Act (ODA) established in 1983 compelled producers to expand scale to treat uncommon/orphan diseases, and the orphan drug panorama has advanced drastically. Approvals for orphan drugs has doubled in the past decade, and there are over 500 applicants in the pipeline for orphan diseases.
The 3rd Annual MarketsandMarkets Orphan Drugs and Rare Diseases Conference Virtual Event is scheduled to be held on 15th -16th March 2022 will provide valuable and necessary platform for uplifting knowledge at the forefront of drug analysis.
Over the course of the conference, internationally renowned speakers can describe how their analysis journeys have developed the response towards up-to-date challenges. The attending specialists and trade partners will offer an incredible networking expertise.
This conference will gather scientists, researchers, entrepreneurs, academicians, medical officers, CEO’s, CSO’s and technologists from everywhere around the globe to discuss on the newest scientific advances within the field of rare diseases & orphan drugs that facilitate to form current and future challenges in drug analysis.
Senior Director, Patient Advocacy and Industry Relations, Acadia Pharmaceuticals Inc.
Vice President and General Manager, Germany and Central / Eastern Europe , Ultragenyx Pharmaceutical Inc.
Non-Executive Director, Omnispirant Therapeutics
Senior Director, Patient Advocacy and Industry Relations, Acadia Pharmaceuticals Inc.
Vice President and General Manager, Germany and Central / Eastern Europe , Ultragenyx Pharmaceutical Inc.
Non-Executive Director, Omnispirant Therapeutics
Chief Executive Officer, WPD Pharmaceuticals Inc
.jpg)
Head of Patient Value Access & Public Affairs, Takeda Pharmaceuticals
Assistant Professor of Surgery, Harvard Medical School, Partner, Mainspring Venture Partners
Associate Director for Global Medical Affairs |Project Lead, MIT-Takeda Program on Fabry
.jpg)
Managing Director and Vice President of Operations, Tailored Clinical Research Solutions (TCRS)
